A Placebo-controlled, Single Blind, Randomised, Phase I, First In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level

Trial Profile

A Placebo-controlled, Single Blind, Randomised, Phase I, First In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs CiVi-007 (Primary)
  • Indications Hypercholesterolaemia
  • Focus First in man; Therapeutic Use
  • Sponsors CiVi Biopharma
  • Most Recent Events

    • 13 Feb 2018 New trial record
    • 03 Feb 2018 According to a CiVi Biopharma media release, the first patient is expected to be dosed in 2018. Data from this trial is expected in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top